Appendix 4D

Half Year Report to the Australian Stock Exchange

Name of Entity	BTC health Limited
ABN	45 091 979 172
Half Year Ended	31 December 2020
Previous Corresponding	31 December 2019
Reporting Period	

Results for Announcement to the Market

	31/12/2020 \$'000	31/12/2019 \$'000	Percentage increase / (decrease) over previous corresponding period
Revenue from ordinary activities	19	182	(89.56%)
Profit / (loss) from ordinary activities after tax attributable to members	(179)	(221)	(19.00%)
Net profit / (loss) for the period attributable to members	(179)	(221)	(19.00%)

Dividends	Amount per secur	ity Franked amount per
(distributions)		security
Dividend 31/12/20	Nil	Nil
Interim Dividend	Nil	Nil
Record date for determine	ning entitlements	
to the dividends (if any)	N/.	A

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

The company made a loss after tax during the half-year of \$178,942 (Dec 2019: \$221,288). The company sold its investment in Bio101group Pty Ltd on 31 July 2020 for \$500,000 cash, being the fair value of the investment at 30 June 2020. Revenue of \$18,941 (Dec 2019: \$181,611) largely comprises Management Fees

received from Bio101group. Expenses for the half-year were reduced to \$197,883 (Dec 2019: \$402,899) and reflect running costs of the company. Cash balances at 31 December 2020 were \$2,316,405 (June 2020: \$2,750,289).

BTC held active interests in two investment companies at 31 December 2020, BTC Speciality Health Pty Ltd and BioImpact Pty Ltd. The valuation of each investee company is recognised on the balance sheet.

Dividends

Date the dividend is payable	N/A
Record date to determine	
entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign	
sourced dividend or distribution	N/A
Details of any dividend reinvestment	
plans in operation	N/A
The last date for receipt of an	
election notice for participation in	
any dividend reinvestment plans	N/A

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	4.49 cents	4.56 cents

Control Gained Over Entities Having Material Effect

	<u> </u>
Name of entity (or group of entities)	None
Date control gained	N/A
Consolidated profit / (loss) from	N/A
ordinary activities since the date in the	
current period on which control was	
acquired	
Profit / (loss) from ordinary activities of	N/A
the controlled entity (or group of	
entities) for the whole of the previous	
corresponding period	

Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	None
Date control lost	N/A

Consolidated profit / (loss) from	N/A
ordinary activities for the current period	
to the date of loss of control	
Profit / (loss) from ordinary activities of	N/A
the controlled entity (or group of	
entities) while controlled for the whole	
of the previous corresponding period	

Details of Associates and Joint Venture Entities

Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
None	N/A	N/A	N/A	N/A
Aggregate Share of Net Profits	N/A	N/A	N/A	N/A

	Foreig	yn Entitie	s Accountir	ng Framework	
--	--------	------------	-------------	--------------	--

Foreign Entities Accounting Framework
For foreign entities provide details of which accounting standards have been adopted (e.g. International Accounting Standards)
N/A

Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)				
The accounts have been audited	The accounts have been subject to review	√		
If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification: N/A				

Attachments Forming Part of Appendix 4D

Attachment #	Details	
1	Interim Financial Report	
Signed by Com	pany Secretary	SIK
Print Name		Sharon Papworth
Date		16 February 2021

ABN 45 091 979 172

HALF-YEAR FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

CONTENTS

CORPORATE DIRECTORY	.3
DIRECTORS' REPORT	.4
AUDITOR'S INDEPENDENCE DECLARATION	.6
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE	
STATEMENT OF FINANCIAL POSITION	.8
STATEMENT OF CASH FLOWS	.9
STATEMENT OF CHANGES IN EQUITY1	0
NOTES TO THE FINANCIAL STATEMENTS1	1
DIRECTORS' DECLARATION1	16
NDEPENDENT AUDITOR'S REVIEW REPORT1	17

CORPORATE DIRECTORY

Principal and registered office in BTC health Limited

Australia Level 1, 10 Oxley Road

Hawthorn VIC 3122 T 1800 100 282

Directors Richard Treagus

Jonathan Pilcher Bruce Hewett

Company Secretary Sharon Papworth

Bankers Westpac Banking Corporation

Share Register Link Market Services

Tower 4, 727 Collins Street MELBOURNE VIC 3008

Locked Bag A14

SYDNEY SOUTH NSW 1235

T 1300 554 474 F (02) 9287 0303

Auditor Grant Thornton

Collins Square, Tower 5 727 Collins Street

MELBOURNE VIC 3008

Internet Address <u>www.btchealth.com.au</u>

HALF-YEAR FINANCIAL REPORT

DIRECTORS' REPORT

Your directors submit the financial report of the company for the half-year ended 31 December 2020.

Directors

Richard Treagus Jonathan Pilcher Bruce Hewett

Review of Operations

The following is a review of operations for the six-month period to 31 December 2020:

The company made a loss after tax during the half-year of \$178,942 (Dec 2019: \$221,288). The company sold its investment in Bio101group Pty Ltd on 31 July 2020 for \$500,000 cash, being the fair value of the investment at 30 June 2020. Revenue of \$18,941 (Dec 2019: \$181,611) largely comprises Management Fees received from Bio101group. Expenses for the half-year were reduced to \$197,883 (Dec 2019: \$402,899) and reflect running costs of the company. Cash balances at 31 December 2020 were \$2,316,405 (June 2020: \$2,750,289).

BTC held active interests in two investment companies at 31 December 2020, BTC Speciality Health Pty Ltd and BioImpact Pty Ltd. The valuation of each investee company is recognised on the balance sheet.

BTC Speciality Health Pty Ltd

BTC health's wholly owned investee company BTC Speciality Health is an established distributor of medical devices and consumables in the Australian and New Zealand Public and Private Hospital market. Sales to Hospitals were \$3.6m for the half-year ended December 2020 and grew 9.0% over prior year (Dec 19: \$3.3m). Sales growth was particularly pleasing given the impact of elective surgery closure earlier in the financial year and the Prosthesis List Price decline of 5.0%, which took place on 1 February 2020. Freight initiatives and a stronger Australian Doller helped offset the gross margin impact of the Prosthesis List price reduction. Overheads continue to be tightly controlled and were favourable 4% against prior year and 8% against plan. The investment is valued at \$6,000,000.

BioImpact Pty Ltd

BTC health wholly owns BioImpact, an investment company which licenses and holds intellectual property rights for healthcare products. The investment is valued at \$100.

BTC health sold its non-core investment in BIO101 Group Pty Ltd on 31 July 2020 for \$500,000 cash, being a 500.0% return on BTC health's initial investment in 2016.

BTC health is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992.

Subsequent Events

No matters have arisen between the end of the half-year ended 31 December 2020 and the date of this report which in the opinion of the directors of the company, will affect significantly the operations of the entity, the results of those operations, or the state of the affairs of the entity in subsequent financial years.

Auditor's Declaration of Independence

A copy of the auditor's declaration under section 307C in relation to the half year is included on page 6. This report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

Richard Treagus Executive Chairman

Dated 16th February 2021



Collins Square, Tower 5 727 Collins Street Melbourne VIC 3008

Correspondence to: GPO Box 4736 Melbourne VIC 3001

T +61 3 8320 2222 F +61 3 8320 2200 E info.vic@au.gt.com W www.grantthornton.com.au

Auditor's Independence Declaration

To the Directors of BTC Health Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of BTC Health Limited for the half year ended 31 December 2020, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
- b no contraventions of any applicable code of professional conduct in relation to the audit.

Grant Thornton Audit Pty Ltd Chartered Accountants

In get Thompson

M A Cunningham
Partner – Audit & Assurance

Melbourne, 16 February 2021

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

	31 December 2020 \$	31 December 2019 \$
Revenue	·	·
Interest income	608	6,611
Management Fee	13,333	80,000
Increase in fair value of investment (Note 2)	-	95,000
Other income	5,000	-
	18,941	181,611
Expenses		
Executive Director fees	(90,000)	(204,974)
Non-Executive Director fees	(30,000)	(36,860)
Listing fees	(24,973)	(35,753)
Share registry	(3,680)	(10,069)
Share based payments	-	(9,588)
Insurance	(19,063)	(16,549)
Legal Fees	(3,800)	(1,473)
Audit Fees	(15,844)	(15,000)
Accounting and company secretarial	<u>-</u>	(46,281)
Other expenses from operations	(10,523)	(26,352)
	(197,883)	(402,899)
Loss before income tax expense	(178,942)	(221,288)
Income tax benefit	-	
Loss for the period	(178,942)	(221,288)
Other comprehensive income		
TOTAL COMPREHENSIVE LOSS FOR THE		
PERIOD	(178,942)	(221,288)
Basic loss per share (cents per share)	(0.07)	(0.09)
Diluted loss per share (cents per share)	(0.07)	(0.09)

The accompanying notes form part of this financial report.

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2020

	31 December 2020 \$	30 June 2020 \$
CURRENT ASSETS		
Cash and cash equivalents	2,316,405	2,750,289
Other financial assets (Note 2)	20.462	500,000
Other assets TOTAL CURRENT ASSETS	20,462 2,336,867	107,484 3,357,773
TOTAL CURRENT ASSETS	2,330,007	3,331,113
NON CURRENT ASSETS		
Financial assets (Note 2)	6,000,100	6,000,100
Loans to investee companies (Note 3)	2,884,884	2,099,057
TOTAL NON CURRENT ASSETS	8,884,984	8,099,157
TOTAL ASSETS	11,221,851	11,456,930
CURRENT LIABILITIES		
Trade and other payables	65,272	121,409
Unclaimed monies	106,727	106,727
TOTAL CURRENT LIABILITIES	171,999	228,136
TOTAL LIABILITIES	171,999	228,136
NET ASSETS	11,049,852	11,228,794
EQUITY	E2 00E 040	E2 26E 642
Issued capital (Note 4) Other reserves	53,265,612 171,858	53,265,612 214,846
Accumulated losses	(42,387,618)	(42,251,664)
, todamatod loodd	(12,007,010)	(12,201,004)
TOTAL EQUITY	11,049,852	11,228,794

The accompanying notes form part of this financial report

STATEMENT OF CASH FLOWS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

	31 December 2020 \$	31 December 2019 \$
CASH FLOWS FROM OPERATING ACTIVITIES		
Interest received	608	6,611
Payments to suppliers and employees	(211,714)	(130,185)
Net cash used in operating activities	(211,106)	(123,574)
CASH FLOWS FROM INVESTING ACTIVITIES		
Loan advanced to investee companies	(722,778)	(290,315)
Proceeds from sale of Bio10group Pty Ltd	500,000	-
Net cash used in investing activities	(222,778)	(290,315)
CASH FLOW FROM FINANCING ACTIVITIES		
Share placement costs	-	(23,004)
Unclaimed monies paid	-	(113,107)
Net cash used in financing activities	-	(136,111)
Net decrease in cash and cash equivalents held	(433,884)	(550,000)
Cash and cash equivalents at beginning of the half-year	2,750,289	3,942,921
Cash and cash equivalents at end of half-year	2,316,405	3,392,921

The accompanying notes form part of this financial report

STATEMENT OF CHANGES IN EQUITY FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

	Issued capital	Accumulated Losses	Other reserves	Total
	\$	\$	\$	\$
At 1 July 2019 Loss for the period Other comprehensive income	53,104,855 -	(42,110,284) (221,288)	346,914 -	11,341,485 (221,288)
Total comprehensive loss for the period Transactions with owners in their		(221,288)	-	(221,288)
capacity as owners: Share based payments At 31 December 2019	183,078 53,287,933	60,803 (42,270,769)	(51,215) 295,699	192,666 11,312,863
At 1 July 2020 Loss for the period	53,265,612 -	(42,251,664) (178,942)	214,846 -	11,228,794 (178,942)
Other comprehensive income Total comprehensive loss for the period Transactions with owners in their capacity as owners:		(178,942)	-	(178,942)
Expiry of share options At 31 December 2020	53,265,612	42,988 (42,387,618)	(42,988) 171,858	11,049,852

The accompanying notes form part of this financial report

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

Note 1: Significant Accounting Policies

Statement of compliance

The half-year financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standards IAS 34 Interim Financial Reporting.

The half-year financial report does not include all notes of the type normally included within the full financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial report.

It is recommended that this financial report be read in conjunction with the annual financial report for the year ended 30 June 2020 and any announcements made by BTC health Limited during the half-year in accordance with continuous disclosure requirements arising under the *Corporations Act 2001*.

Basis of Preparation

The financial report of BTC health Limited for the half-year ended 31 December 2020 was authorised for issue in accordance with a resolution of the directors on 16 February 2021. BTC health Limited is a company incorporated in Australia and limited by shares which are publicly traded on the Australian Securities Exchange.

The accounting policies have been consistently applied and are consistent with those applied in the 30 June 2020 annual report, except for the adoption of new or revised standards mandatory for annual periods beginning on or after 1 July 2020, as noted below.

The half-year financial report has been prepared on a historical cost basis, except for financial assets that have been measured at fair value. For the purpose of preparing the half-year financial report, the half-year has been treated as a discrete reporting period.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

Note 1: Significant Accounting Policies - Continued

Adoption of new and revised Accounting Standards

The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 2: Financial Assets

	31 December 2020 \$	30 June 2020 \$
Financial assets carried at fair value through profit or loss Current:		
Bio101group Pty Ltd	-	500,000
Non-Current:		
BioImpact Pty Ltd	100	100
BTC Speciality Health Pty Ltd	6,000,000	6,000,000
Total Non- Current Financial Assets	6,000,100	6,500,100

Fair value of financial instruments: Valuation techniques and assumptions applied for the purposes of measuring fair value

The fair values of unlisted investments are determined in accordance by directors' valuations, which are based on their experience in the industry. Directors have used assumptions, such as estimated cash flows, project plans and other market data available in determining their valuation of unlisted investments. Should these assumptions change in subsequent periods the fair value may be impacted and accounted for through the profit or loss. The directors have reviewed discounted cash flows and multiple of revenue and profit calculations to determine the fair value holding costs of the investments.

BTC sold it's investment in Bio101Group Pty Ltd, a non-core investment which provides accounting, taxation and company secretarial services to companies in the life sciences and healthcare sector. The transaction was completed on 31 July 2020 for \$500,000 cash, which represents a 500% return on BTC health's initial investment in 2016, and consistent with the valuation recognised in BTC health's accounts at 30 June 2020.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

Name of Investment	Core Activity
BioImpact Pty Ltd	Invests in and holds intellectual property rights for pharmaceuticals and medical devices for the development and commercialisation in the Asia/Pacific region. Technologies and products are sourced form a range of global third parties.
BTC Speciality Health Pty Ltd	Commercialises and distributes the BTC health group's in- licensed pharmaceuticals and medical devices in the Asia/Pacific region.

Fair value measurements recognised in the statement of financial position:

The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 based on the degree to which the fair value is observable.

- a) Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1	Level 2	Level 3	Total
31 December 2020	\$	\$	\$	\$
Financial assets Unlisted investments– Financial assets				
carried at fair value through profit or loss	-	-	6,000,100	6,000,100
	-	-	6,000,100	6,000,100
30 June 2020				
Financial assets Unlisted investments– Financial assets				
carried at fair value through profit or loss	-	-	6,500,100	6,500,100
	-	-	6,500,100	6,500,100
There were no transfers between levels durin	g the year.			

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

Note 3: Loans to investee companies

	31 December 2020 \$	30 June 2020 \$
Non- Current		
Loans to investee companies		
BioImpact Pty Ltd	553,826	555,707
BTC Speciality Health Pty Ltd	2,331,058	1,543,350
Total Loans to investee companies	2,884,884	2,099,057

Note 4: Issued Capital

	31 December 2020	31 December 2020	30 June 2020	30 June 2020
	Shares	\$	Shares	\$
Movement Opening balance	246,132,068	53,265,612	244,542,783	53,104,855
Share Placement 3 July 2019 Capital raising costs	-	- -	625,000	50,000 (1,922)
Share issue 27 August 2019 Share issue 2 December 2019	-	-	71,428 892,857	10,000 102,679
Closing balance	246,132,068	53,265,612	246,132,068	53,265,612

Note 5: Contingent Liabilities

There were no material contingent liabilities of which the Company is aware of at the date of this report.

Note 6. Related party transactions

BTC health received management fee income from consulting services to Bio101group Pty Ltd during the half-year of \$13,333 (2019: \$80,000). The trade debtors receivable from Bio101group Pty Ltd were settled on date of sale, being 31 July 2020.

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2020

Note 7: Subsequent Events

No material matters have arisen between the end of the half-year ended 31 December 2020 and the date of this report which in the opinion of the directors of the company, will affect significantly the operations of the entity, the results of those operations, or the state of the affairs of the entity, in subsequent financial years.

Note 8: Segment Information

Operating and reportable segments have been identified on the basis of internal reports of the company that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segments and to assess their performance. The chief operating decision maker has been identified as the Executive Chairman.

The company has single and reportable operating segment being investments in biotechnology and pharmaceutical ventures.

DIRECTORS' DECLARATION

The directors declare that:


- (a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- (b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the Corporations Act 2001, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Company.

Signed in accordance with a resolution of the Board of Directors made pursuant to s.303(5) of the Corporations Act 2001.

On behalf of the directors,

Richard Treagus Executive Chairman

Dated 16th February 2021



Collins Square, Tower 5 727 Collins Street Melbourne VIC 3008

Correspondence to: GPO Box 4736 Melbourne VIC 3001

T +61 3 8320 2222 F +61 3 8320 2200 E <u>info.vic@au.gt.com</u> W www.grantthornton.com.au

Independent Auditor's Report

To the Members of BTC Health Limited

Report on the review of the half year financial report

Conclusion

We have reviewed the accompanying half year financial report of BTC Health Limited (the Company), which comprises the statement of financial position as at 31 December 2020, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, nothing has come to our attention that causes us to believe that the half year financial report of BTC Health Limited does not give a true and fair view of the financial position of the Company as at 31 December 2020, and of its financial performance and its cash flows for the half year ended on that date, in accordance with the *Corporations Act 2001*, including complying with Accounting Standard AASB 134 *Interim Financial Reporting*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 Review of Financial Report Performance by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We confirm that the independence declaration required by the Corporations Act 2001 which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Directors' responsibility for the half year financial report

The Directors of the Company are responsible for the preparation of the half year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

www.grantthornton.com.au

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.



Auditor's responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Company's financial position as at 31 December 2020 and its performance for the half year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of BTC Health Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton Audit Pty Ltd Chartered Accountants

I want Thombor

M A Cunningham

Partner - Audit & Assurance

Melbourne, 16 February 2021